Sumatriptan succinate

Generic Name: Sumatriptan succinate
Brand Name: -
Dosage Form: Injection 6mg/0.5ml
Pharmacological Category: Selective 5-hydroxytryptamine1 (5-HT1) agonist
Therapeutic Category: Vascular headache suppressant
Pregnancy Category: category C

Pharmacology

Selectively activates vascular 5-HT1 receptor sites, causing vasoconstriction in intracranial arteries

Pharmacokinetics:

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

Indications:

Acute migraine

Contraindications:

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

Precautions:

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

Drug Interactions:

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

Side Effects:

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

Storage:

• Store below 30 C°
• Protect from light and freezing

Packing:

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

stdClass Object ( [nid] => 213 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373496119 [changed] => 1377183612 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 96 [translate] => 0 [vid] => 213 [revision_uid] => 1 [title] => Sumatriptan succinate [body] =>
Image: 
Brand Name: 

-

Dosage Form: 

Injection 6mg/0.5ml

Pharmacological Category: 

Selective 5-hydroxytryptamine1 (5-HT1) agonist

Therapeutic Category: 

Vascular headache suppressant

Pregnancy Category: 

category C

Selectively activates vascular 5-HT1 receptor sites, causing vasoconstriction in intracranial arteries

Pharmacokinetics: 

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

Indications: 

Acute migraine

Contraindications: 

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

Precautions: 

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

Drug Interactions: 

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

Side Effects: 

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[log] => [revision_timestamp] => 1377183612 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-aTcSqa5gxC3qlJ6qWYJHsxgkPEq9KwPBBC-KEX1q3PQ";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/sumatriptan-succinate [field_one_image] => Array ( [0] => Array ( [fid] => 153 [uid] => 1 [filename] => sumatriptan-900706_s.jpg [filepath] => sites/default/files/images/sumatriptan-900706_s.jpg [filemime] => image/jpeg [filesize] => 44406 [status] => 1 [timestamp] => 1329482235 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 213 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => - [format] => 1 [safe] =>

-

[view] =>

-

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Hypersensitivity to drug • Hemiplegic or basilar migraine headache • Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel) • Uncontrolled hypertension • Severe hepatic impairment • MAO inhibitor use within past 14 days • Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours [format] => 1 [safe] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

[view] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 6mg/0.5ml [format] => 1 [safe] =>

Injection 6mg/0.5ml

[view] =>

Injection 6mg/0.5ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination [format] => 1 [safe] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

[view] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

) ) [field_indications] => Array ( [0] => Array ( [value] => Acute migraine [format] => 1 [safe] =>

Acute migraine

[view] =>

Acute migraine

) ) [field_packing] => Array ( [0] => Array ( [value] => Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box [format] => 1 [safe] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[view] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 154 [uid] => 1 [filename] => sumatriptan.pdf [filepath] => sites/default/files/pdf/sumatriptan.pdf [filemime] => application/pdf [filesize] => 419432 [status] => 1 [timestamp] => 1329482464 [list] => 1 [data] => [i18nsync] => 1 [nid] => 213 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate. [format] => 1 [safe] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

[view] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Selective 5-hydroxytryptamine1 (5-HT1) agonist [format] => 1 [safe] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

[view] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

) ) [field_precautions] => Array ( [0] => Array ( [value] => Use cautiously in: • patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women) • elderly patients • women of childbearing age • pregnant or breastfeeding patients • children younger than age 18 (safety not established). [format] => 1 [safe] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

[view] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => category C [format] => 1 [safe] =>

category C

[view] =>

category C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction EENT: vision changes, nasal sinus discomfort, throat discomfort GI: abdominal discomfort, dysphagia Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness Skin: flushing; tingling; warm, cool or, burning sensation Other: injection site reaction, feeling of heaviness or tightness [format] => 1 [safe] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

[view] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Vascular headache suppressant [format] => 1 [safe] =>

Vascular headache suppressant

[view] =>

Vascular headache suppressant

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [2] => stdClass Object ( [tid] => 2 [vid] => 1 [name] => Anlagesics, Anti-inflammatory Drugs [description] => [weight] => 0 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 153 [uid] => 1 [filename] => sumatriptan-900706_s.jpg [filepath] => sites/default/files/images/sumatriptan-900706_s.jpg [filemime] => image/jpeg [filesize] => 44406 [status] => 1 [timestamp] => 1329482235 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 213 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => - [format] => 1 [safe] =>

-

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

-

) [#title] => [#description] => [#children] =>

-

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

-

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

-

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 6mg/0.5ml [format] => 1 [safe] =>

Injection 6mg/0.5ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 6mg/0.5ml

) [#title] => [#description] => [#children] =>

Injection 6mg/0.5ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 6mg/0.5ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 6mg/0.5ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Selective 5-hydroxytryptamine1 (5-HT1) agonist [format] => 1 [safe] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

) [#title] => [#description] => [#children] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Selective 5-hydroxytryptamine1 (5-HT1) agonist

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Selective 5-hydroxytryptamine1 (5-HT1) agonist

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Vascular headache suppressant [format] => 1 [safe] =>

Vascular headache suppressant

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Vascular headache suppressant

) [#title] => [#description] => [#children] =>

Vascular headache suppressant

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Vascular headache suppressant

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Vascular headache suppressant

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => category C [format] => 1 [safe] =>

category C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

category C

) [#title] => [#description] => [#children] =>

category C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

category C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

category C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

Selectively activates vascular 5-HT1 receptor sites, causing vasoconstriction in intracranial arteries

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate. [format] => 1 [safe] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

) [#title] => [#description] => [#children] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Acute migraine [format] => 1 [safe] =>

Acute migraine

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Acute migraine

) [#title] => [#description] => [#children] =>

Acute migraine

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Acute migraine

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

Acute migraine

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Hypersensitivity to drug • Hemiplegic or basilar migraine headache • Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel) • Uncontrolled hypertension • Severe hepatic impairment • MAO inhibitor use within past 14 days • Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours [format] => 1 [safe] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

) [#title] => [#description] => [#children] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Use cautiously in: • patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women) • elderly patients • women of childbearing age • pregnant or breastfeeding patients • children younger than age 18 (safety not established). [format] => 1 [safe] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

) [#title] => [#description] => [#children] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Precautions: 

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

[#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination [format] => 1 [safe] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

) [#title] => [#description] => [#children] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction EENT: vision changes, nasal sinus discomfort, throat discomfort GI: abdominal discomfort, dysphagia Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness Skin: flushing; tingling; warm, cool or, burning sensation Other: injection site reaction, feeling of heaviness or tightness [format] => 1 [safe] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

) [#title] => [#description] => [#children] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box [format] => 1 [safe] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

) [#title] => [#description] => [#children] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 154 [uid] => 1 [filename] => sumatriptan.pdf [filepath] => sites/default/files/pdf/sumatriptan.pdf [filemime] => application/pdf [filesize] => 419432 [status] => 1 [timestamp] => 1329482464 [list] => 1 [data] => [i18nsync] => 1 [nid] => 213 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

-

Dosage Form: 

Injection 6mg/0.5ml

Pharmacological Category: 

Selective 5-hydroxytryptamine1 (5-HT1) agonist

Therapeutic Category: 

Vascular headache suppressant

Pregnancy Category: 

category C

Selectively activates vascular 5-HT1 receptor sites, causing vasoconstriction in intracranial arteries

Pharmacokinetics: 

Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism. Absorption is rapid after subcutaneous injection, with peak concentration reached in 10 minutes. Less than 20% of the drug is protein bound. The volume of distribution is greater than total body water at 170L. Total plasma clearance is rapid, with an elimination half-life of around 2 hours. There is one major metabolite (an indole acetic acid analogue) which is excreted in the urine as the free acid and its ester glucuronide conjugate.

Indications: 

Acute migraine

Contraindications: 

• Hypersensitivity to drug
• Hemiplegic or basilar migraine headache
• Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
• Uncontrolled hypertension
• Severe hepatic impairment
• MAO inhibitor use within past 14 days
• Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

Precautions: 

Use cautiously in:
• patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, amily history of cardiovascular disease, men over age 40, menopausal women)
• elderly patients
• women of childbearing age
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

Drug Interactions: 

Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination

Side Effects: 

CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

Sumatriptan Injection 6mg / 0.5ml : 1 ampoule/box

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/96 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => سوماتریپتان سوکسینات [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517